Emerald Advisers’s Harmony Biosciences HRMY Stock Holding History

Emerald Advisers’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$13.8M	Buy	+351,283	New	+$13.6M	0.38%	101

Other funds holding HRMY

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Capital Management Glen Allen, Virginia $668M AUM 8.93% 1-Year Est. Return

Bridge City Capital Lake Oswego, Oregon $480M AUM 47.16% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

Emerald Advisers's HRMY Position: Q3 2026 in Review

Emerald Advisers opened a new position in Harmony Biosciences (HRMY) in Q3 2026: 351,283 shares worth $13.8M. The stake represents 0.38% of the portfolio and ranks #101 among its holdings.

147 funds tracked by Wall St. Rank hold HRMY as of Q3 2026.

Emerald Advisers held 351,283 shares of Harmony Biosciences worth $13.8M as of Q3 2026.
Harmony Biosciences was a new Emerald Advisers position in Q3 2026.
Harmony Biosciences made up 0.38% of Emerald Advisers's portfolio in Q3 2026, its #101 holding.
147 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2026.

Based on Emerald Advisers's 13F filing for Q3 2026, filed 9 Nov 2026.